71239-64-0

Usage

Uses

Used in Pharmaceutical Industry:
Flustramine A is used as a pharmaceutical compound for its potential therapeutic applications. flustramine A's unique structure and properties make it a promising candidate for the development of new drugs targeting various diseases.
Used in Research and Development:
Flustramine A is used as a research tool for studying the chemical properties and biological activities of brominated alkaloids. Its isolation and purification from the marine source provide valuable insights into the natural products chemistry and their potential applications in drug discovery.
Used in Drug Delivery Systems:
Similar to gallotannin, flustramine A could potentially be used in drug delivery systems to enhance its bioavailability and therapeutic outcomes. The development of novel drug delivery systems, such as organic and metallic nanoparticles, could improve the delivery and efficacy of flustramine A in targeted applications.

InChI:InChI=1/C21H29BrN2/c1-7-20(4,5)21-11-13-23(6)19(21)24(12-10-15(2)3)18-14-16(22)8-9-17(18)21/h7-10,14,19H,1,11-13H2,2-6H3/t19-,21-/m1/s1

Upstream product

• 82534-44-9 (3aR,8aS)-6-bromo-1-methyl-8-(3-methylbut-2-enyl)-3a-(2-methylbut-3-en-2-yl)-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one 
• 850210-81-0 (4S)-2-Methyl-2-decen-4-ol 
• 877797-52-9 C₂₁H₂₇BrN₂O₂ 
• 877797-51-8 C₂₀H₂₄BrNO₃ 
• 877797-50-7 2-(6-bromo-1-(3-methylbut-2-en-1-yl)-3-(2-methylbut-3-en-2-yl)-2-oxoindolin-3-yl)acetonitrile 
• 877797-54-1 C₁₉H₂₁BrN₂O₂ 
• 877797-49-4 C₁₄H₁₃BrN₂O₂ 
• 877797-48-3 2-{(R)-6-bromo-3-[(E)-methyldec-3-en-2-yl]-2-oxoindolin-3-yl}acetonitrile 
• 877797-47-2 C₂₁H₂₈BrNO₃ 
• 877797-53-0 C₁₇H₃₆OSi 

Relevant academic research and scientific papers

Enantioselective total synthesis of (-)-flustramines A, B and (-)-flustramides A, B via domino olefination/isomerization/Claisen rearrangement sequence

The concise total synthesis of marine alkaloids, (-)-flustramines A and B, and (-)-flustramides A and B has been achieved through the domino olefination/isomerization/Claisen rearrangement (OIC) for highly enantioselective construction of the asymmetric quaternary carbon center and the chemoselective reduction-cyclization (RC) for pyrrolidine formation as key steps. The Royal Society of Chemistry 2006.